Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (CTXR) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
ctxr · stock forecast · 6 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 6 Wall Street analysts in the past 3 months
Buy
6 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.59
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.56 | ↓ 5.00% |
1-day model range: $0.55–$0.57. Peak: $0.57 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CTXR · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-11 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-12-04 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-08-13 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-06-30 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-06-10 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-06-09 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-05-23 | Maxim Group | Downgrade ↓ | Buy→Hold |
| 2025-05-15 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-02-18 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-01-07 | D. Boral Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Citius Pharmaceuticals, Inc. (CTXR) stock. Of the recent 29 rating actions, 1 were upgrades and 2 were downgrades. 6 analysts currently cover CTXR.
Analyst Recommendation Trends
CTXR analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$21M
↓ 80.1% YoY
Revenue Next Year
$53M
↑ 152.3% YoY
EPS This Year
$-1.87
EPS Next Year
$-0.81
↓ 56.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast CTXR EPS of $-1.87 for the current fiscal year, based on estimates from 1 analysts. The CTXR revenue forecast is $21M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CTXR stock forecast is supported by two independent data sources: analyst consensus ratings from 6 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CTXR price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The CTXR short-term stock prediction for tomorrow is $0.56 (-5.00%).
Citius Pharmaceuticals, Inc. trades on NASDAQ under the ticker CTXR. The CTXR stock outlook for 2027 is broadly positive, supported by a Buy consensus among 83% of covering analysts.
Frequently asked questions
CTXR forecast · 8 questionsAccording to 6 Wall Street analysts, the average 12-month CTXR price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.59.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.